GLEN ROCK, NJ–(Marketwired – November 15, 2016) -– RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its September 30, 2016 Quarterly Report on Form 10-Q and is hereby providing an update on the Company’s ongoing…
Glen Rock, N.J., October 17, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression and sleep apneas, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at…
Data is in Process of Being Re-Analyzed Updated Report Expected to be Issued by the End of 2016 Glen Rock, N.J., October 4, 2016/Globe Newswire – On September 12, 2016, RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”) issued a press release announcing preliminary top-line analysis of safety and efficacy data from a Phase…
Glen Rock, N.J., September 12, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPID and OTCQB: RSPI) (“RespireRx” or the “Company”) is a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression (RD) and sleep apneas. RespireRx is today reporting preliminary top-line data from its Phase 2A clinical trial of CX1739, the…
Glen Rock, N.J., September 8, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression and sleep apneas, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present…
Glen Rock, N.J., September 1, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, today announced that the Company is effecting the one-for-three-hundred–twenty-five reverse stock split of the Company’s issued and outstanding common stock (the…
Glen Rock, N.J., August 15, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its June 30, 2016 Quarterly Report on Form 10-Q and is hereby providing an update on the Company’s ongoing…